Infographic
October 28, 2026

2026 Patient Recruitment Roundup

Key findings of the 2026 Patient Recruitment Roundup:

Overall MER fell to a four-year low, Phase IV trials lead enrollment, enrollment duration has risen sharply, Asia outperforms across the board, vaccines are the fastest-enrolling trials, and non-industry trials surpass industry-sponsored trials.

Functional cookies are required to display this PDF. Update your cookie preferences to view it, or download the PDF directly.

FAQ

MER is the median number of patients enrolled per site per month across all trials with available actual enrollment data. It reflects real-world recruitment performance rather than planned enrollment. The combined MER for industry-sponsored patient trials from 2022 to 2025 was 0.37 patients/site/month.
Overall median enrollment rates (MER) fell to a four-year low of 0.32 in 2024 and recovered modestly to 0.36 in 2025. In 2010, MER was 0.76, roughly double current levels. Enrollment duration has also risen in every phase since 2010, and Phase I more than doubled.
Phase IV trials lead on enrollment (MER 0.70–1.04), and Asian sites outperform North American and European sites in every phase and year studied. Infectious disease vaccine trials record the highest rates, up to a MER of 5.38 in 2025. Oncology and rare disease trials record the lowest rates (0.16–0.22). Small molecules also enroll faster than biologics.

Get in touch

Have a question or need more detail? Tell us what you’re looking for, and our team will be in touch shortly.

Choose a time to talk

専門家との相談日時を選択

Calendar requires cookies. Enable cookies

カレンダーの表示にはCookieの有効化が必要です Cookieを有効にする

Or send us a message and we'll be in touch

面談の有無がお決まりでない場合は、お問い合わせ内容をお送りください。担当者よりご連絡いたします。